No unexpected safety issues were observed, and complete response (or complete response with incomplete peripheral blood count recovery) was observed in 50% of patients in the AML cohort.268 Then, targeting CD38 presents a promising strategy that may additionally hold potential benefits for a variety of malignancies.269. The gene discussed is CD38; the disease is acute myeloid leukemia.